Clinical and pathological characteristics of tumors submitted as HGBCL-NOS by local pathology review
| Characteristic . | Total cohort . | Intermediate morphology . | Blastoid morphology . | Unspecified morphology . | P value∗ . |
|---|---|---|---|---|---|
| N = 92 . | n = 51 . | n = 31 . | n = 10 . | ||
| Age >60 years, n (%) | 58 (63) | 33 (65) | 17 (55) | 8 (80) | .49 |
| Age, median (range), y | 66.5 (19-90) | 66 (30-90) | 66 (22-89) | 73.5 (19-84) | .48 |
| Male sex, n (%) | 56 (61) | 32 (63) | 21 (68) | 3 (30) | .81 |
| Ann Arbor stage, n (%) | |||||
| I/II | 10 (20) | 7 (25) | 3 (16) | 0 (0) | |
| III/IV | 40 (80) | 21 (75) | 16 (84) | 3 (100) | |
| Missing | 42 | 23 | 12 | 7 | .72 |
| LDH > ULN, n (%) | |||||
| No | 16 (31) | 11 (38) | 3 (17) | 2 (50) | |
| Yes | 35 (69) | 18 (62) | 15 (83) | 2 (50) | |
| Missing | 41 | 22 | 13 | 6 | .19 |
| Extranodal sites, n (%) | |||||
| 0-1 | 33 (55) | 21 (57) | 12 (52) | — | |
| >1 | 27 (45) | 16 (43) | 11 (48) | — | |
| Missing | 32 | 14 | 8 | 10 | .79 |
| ECOG PS, n (%) | |||||
| 0-1 | 26 (55) | 16 (62) | 9 (50) | 1 (33) | |
| 2-4 | 21 (45) | 10 (38) | 9 (50) | 2 (67) | |
| Missing | 45 | 25 | 13 | 7 | .54 |
| IPI, n (%) | |||||
| Low (0-2) | 12 (27) | 9 (33) | 3 (18) | — | |
| High (3-5) | 33 (73) | 18 (67) | 14 (82) | 1 (100) | |
| Missing | 47 | 24 | 14 | 9 | .32 |
| Transformed, n (%) | |||||
| No | 53 (91) | 29 (97) | 18 (86) | 6 (86) | |
| Yes | 5 (9) | 1 (3) | 3 (14) | 1 (14) | |
| Unknown | 34 | 21 | 10 | 3 | .29 |
| Relapse biopsy, n (%) | |||||
| No | 53 (90) | 26 (84) | 20 (95) | 7 (100) | |
| Yes | 6 (10) | 5 (16) | 1 (5) | — | |
| unknown | 33 | 20 | 10 | 3 | .38 |
| IHC | |||||
| CD10 | 65/88 (74%) | 37/48 (77%) | 24/31 (77%) | 4/9 (44%) | 1 |
| BCL6 | 55/71 (77%) | 33/41 (80%) | 14/21 (67%) | 8/9 (89%) | .35 |
| MUM1 | 25/53 (48%) | 13/30 (43%) | 8/14 (57%) | 4/9 (44%) | .52 |
| MYC | 34/54 (63%) | 20/34 (59%) | 10/14 (71%) | 4/6 (67%) | .52 |
| BCL2 | 49/86 (57%) | 25/50 (50%) | 16/27 (59%) | 8/9 (89%) | .48 |
| TDT | 1/49 (2%) | 0/25 (0%) | 1/15 (7%) | 0/9 (0%) | .38 |
| Hans COO, n (%) | |||||
| GCB | 68 (82) | 39 (87) | 25 (86) | 4 (44) | |
| Non-GCB | 15 (18) | 6 (13) | 4 (14) | 5 (56) | |
| Missing | 9 | 6 | 2 | 1 | 1 |
| Ki67, median (range) | 90 (40-100) | 90 (40-100) | 100 (70-100) | 90 (50-100) | .35 |
| EBER ISH positive | 1/49 (2%) | 0/33 (0%) | 1/13 (8%) | 0/3 (0%) | .28 |
| COO, n (%) | |||||
| ABC | 17 (25) | 7 (18) | 5 (25) | 5 (50) | |
| Unclassified | 11 (16) | 7 (18) | 4 (20) | — | |
| GCB | 41 (59) | 25 (64) | 11 (55) | 5 (50) | |
| Missing | 23 | 12 | 11 | — | .75 |
| Refined COO, n (%) | |||||
| ABC | 17 (25) | 7 (18) | 5 (25) | 5 (50) | |
| Unclassified | 6 (9) | 4 (10) | 2 (10) | — | |
| GCB | 15 (22) | 11 (28) | 3 (15) | 1 (10) | |
| DZsig+ | 31 (45) | 17 (44) | 10 (50) | 4 (40) | |
| Missing | 23 | 12 | 11 | — | .69 |
| Rearrangement (FISH) | |||||
| MYC | 43/92 (47%) | 22/51 (43%) | 19/31 (61%) | 2/10 (20%) | .17 |
| BCL2 | 7/86 (8%) | 4/48 (8%) | 1/28 (4%) | 2/10 (20%) | .65 |
| BCL6 | 11/86 (13%) | 8/48 (17%) | 1/28 (4%) | 2/10 (20%) | .14 |
| Cryptic HGBCL-DH-BLC2 | 4/66 (6%) | 3/39 (8%) | 1/19 (5%) | 0/8 (0%) | 1 |
| LymphGen, n (%) | |||||
| EZB | 9 (15) | 4 (12) | 3 (15) | 2 (29) | |
| ST2 | 3 (5) | 1 (3) | 2 (10) | — | |
| BN2 | 2 (3) | 2 (6) | — | — | |
| MCD | 6 (10) | 3 (9) | 3 (15) | — | |
| Other | 40 (66) | 23 (68) | 12 (60) | 5 (71) | |
| Composite | 1 (2) | 1 (3) | — | — | |
| Missing | 31 | 17 | 11 | 3 | .69 |
| Characteristic . | Total cohort . | Intermediate morphology . | Blastoid morphology . | Unspecified morphology . | P value∗ . |
|---|---|---|---|---|---|
| N = 92 . | n = 51 . | n = 31 . | n = 10 . | ||
| Age >60 years, n (%) | 58 (63) | 33 (65) | 17 (55) | 8 (80) | .49 |
| Age, median (range), y | 66.5 (19-90) | 66 (30-90) | 66 (22-89) | 73.5 (19-84) | .48 |
| Male sex, n (%) | 56 (61) | 32 (63) | 21 (68) | 3 (30) | .81 |
| Ann Arbor stage, n (%) | |||||
| I/II | 10 (20) | 7 (25) | 3 (16) | 0 (0) | |
| III/IV | 40 (80) | 21 (75) | 16 (84) | 3 (100) | |
| Missing | 42 | 23 | 12 | 7 | .72 |
| LDH > ULN, n (%) | |||||
| No | 16 (31) | 11 (38) | 3 (17) | 2 (50) | |
| Yes | 35 (69) | 18 (62) | 15 (83) | 2 (50) | |
| Missing | 41 | 22 | 13 | 6 | .19 |
| Extranodal sites, n (%) | |||||
| 0-1 | 33 (55) | 21 (57) | 12 (52) | — | |
| >1 | 27 (45) | 16 (43) | 11 (48) | — | |
| Missing | 32 | 14 | 8 | 10 | .79 |
| ECOG PS, n (%) | |||||
| 0-1 | 26 (55) | 16 (62) | 9 (50) | 1 (33) | |
| 2-4 | 21 (45) | 10 (38) | 9 (50) | 2 (67) | |
| Missing | 45 | 25 | 13 | 7 | .54 |
| IPI, n (%) | |||||
| Low (0-2) | 12 (27) | 9 (33) | 3 (18) | — | |
| High (3-5) | 33 (73) | 18 (67) | 14 (82) | 1 (100) | |
| Missing | 47 | 24 | 14 | 9 | .32 |
| Transformed, n (%) | |||||
| No | 53 (91) | 29 (97) | 18 (86) | 6 (86) | |
| Yes | 5 (9) | 1 (3) | 3 (14) | 1 (14) | |
| Unknown | 34 | 21 | 10 | 3 | .29 |
| Relapse biopsy, n (%) | |||||
| No | 53 (90) | 26 (84) | 20 (95) | 7 (100) | |
| Yes | 6 (10) | 5 (16) | 1 (5) | — | |
| unknown | 33 | 20 | 10 | 3 | .38 |
| IHC | |||||
| CD10 | 65/88 (74%) | 37/48 (77%) | 24/31 (77%) | 4/9 (44%) | 1 |
| BCL6 | 55/71 (77%) | 33/41 (80%) | 14/21 (67%) | 8/9 (89%) | .35 |
| MUM1 | 25/53 (48%) | 13/30 (43%) | 8/14 (57%) | 4/9 (44%) | .52 |
| MYC | 34/54 (63%) | 20/34 (59%) | 10/14 (71%) | 4/6 (67%) | .52 |
| BCL2 | 49/86 (57%) | 25/50 (50%) | 16/27 (59%) | 8/9 (89%) | .48 |
| TDT | 1/49 (2%) | 0/25 (0%) | 1/15 (7%) | 0/9 (0%) | .38 |
| Hans COO, n (%) | |||||
| GCB | 68 (82) | 39 (87) | 25 (86) | 4 (44) | |
| Non-GCB | 15 (18) | 6 (13) | 4 (14) | 5 (56) | |
| Missing | 9 | 6 | 2 | 1 | 1 |
| Ki67, median (range) | 90 (40-100) | 90 (40-100) | 100 (70-100) | 90 (50-100) | .35 |
| EBER ISH positive | 1/49 (2%) | 0/33 (0%) | 1/13 (8%) | 0/3 (0%) | .28 |
| COO, n (%) | |||||
| ABC | 17 (25) | 7 (18) | 5 (25) | 5 (50) | |
| Unclassified | 11 (16) | 7 (18) | 4 (20) | — | |
| GCB | 41 (59) | 25 (64) | 11 (55) | 5 (50) | |
| Missing | 23 | 12 | 11 | — | .75 |
| Refined COO, n (%) | |||||
| ABC | 17 (25) | 7 (18) | 5 (25) | 5 (50) | |
| Unclassified | 6 (9) | 4 (10) | 2 (10) | — | |
| GCB | 15 (22) | 11 (28) | 3 (15) | 1 (10) | |
| DZsig+ | 31 (45) | 17 (44) | 10 (50) | 4 (40) | |
| Missing | 23 | 12 | 11 | — | .69 |
| Rearrangement (FISH) | |||||
| MYC | 43/92 (47%) | 22/51 (43%) | 19/31 (61%) | 2/10 (20%) | .17 |
| BCL2 | 7/86 (8%) | 4/48 (8%) | 1/28 (4%) | 2/10 (20%) | .65 |
| BCL6 | 11/86 (13%) | 8/48 (17%) | 1/28 (4%) | 2/10 (20%) | .14 |
| Cryptic HGBCL-DH-BLC2 | 4/66 (6%) | 3/39 (8%) | 1/19 (5%) | 0/8 (0%) | 1 |
| LymphGen, n (%) | |||||
| EZB | 9 (15) | 4 (12) | 3 (15) | 2 (29) | |
| ST2 | 3 (5) | 1 (3) | 2 (10) | — | |
| BN2 | 2 (3) | 2 (6) | — | — | |
| MCD | 6 (10) | 3 (9) | 3 (15) | — | |
| Other | 40 (66) | 23 (68) | 12 (60) | 5 (71) | |
| Composite | 1 (2) | 1 (3) | — | — | |
| Missing | 31 | 17 | 11 | 3 | .69 |
EBER ISH, Epstein-Barr Virus encoded RNA in situ hybridization; ECOG PS, Eastern Cooperative Oncology Group performance status; IPI, International Prognostic Index; LDH, lactate dehydrogenase; MUM1, multiple myeloma oncogene 1; NA, not available; TDT, terminal deoxynucleotidyl transferase; ULN, upper limit of normal.
Comparison between intermediate and blastoid morphology groups.